{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-335921","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2021-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.751817+00:00","generated_at":"2026-06-28T06:09:38.387287+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Zai Lab appoints Richard Gaynor, MD as independent director and R&D Committee chair","bullets":["Gaynor is President & Chief R&D Officer at BioNTech US; previously 15 years at Lilly Oncology.","He receives $50K annual cash retainer for Board, plus $10K as R&D Committee chair, pro-rated to $6,904 for 2021.","Gaynor received an initial grant of 8,912 restricted ordinary shares on November 19, 2021.","CEO Samantha Du noted Gaynor and Scott Morrison were added to the Board in the past two months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-335921","json":"https://secwatch.observer/filing/0001193125-21-335921.json","markdown":"https://secwatch.observer/filing/0001193125-21-335921.md","text":"https://secwatch.observer/filing/0001193125-21-335921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000119312521335921/0001193125-21-335921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000119312521335921/d244462d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T06:09:38.387287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e93a9639a0","claim":"Richard Gaynor was appointed as Independent Director at Zai Lab Ltd.","evidence_excerpt":"On November 19, 2021 (U.S. Eastern Time), the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Richard Gaynor as an independent director, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704292/000119312521335921/0001193125-21-335921-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}